J B Chemicals and Pharmaceuticals Limited has announced the resignations of two senior management personnel in a regulatory disclosure filed on February 5, 2026. The pharmaceutical company informed the stock exchanges about the departure of key executives from operational and business leadership roles.

Senior Management Changes

The company disclosed that Mr. Kunal Khanna, President – Operations, and Mr. Dilip Singh Rathore, President (India Business), have submitted their resignations. Both executives tendered their resignations on February 5, 2026, with the resignations taking effect from the closing of business hours on March 5, 2026.

Regulatory Compliance

The disclosure was made under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The announcement also complies with the SEBI Master Circular bearing reference number SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, which governs disclosures related to changes in senior management personnel.

Transition Timeline

Both resignations provide a one-month transition period, with the executives continuing in their roles until March 5, 2026. This timeline allows the company to manage the transition of responsibilities and ensure operational continuity during the leadership change.

The company secretary, Sandeep Phadnis, Vice President – Secretarial & Company Secretary, signed the regulatory filing on behalf of J.B. Chemicals & Pharmaceuticals Limited. The disclosure was submitted to BSE Limited under the company's scrip code 506943 and stock symbol JBCHEPHEARM.

J b chemicals and pharmaceuticals Limited has announced the record date for interim dividend eligibility for FY 2025-2026. The company has set February 11, 2026 as the cut-off date to determine which shareholders will be eligible to receive the interim dividend payment.

Record Date Details

The pharmaceutical company has fixed the record date in compliance with Regulation 42 of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulatory requirement ensures transparency in determining dividend eligibility for shareholders.

Regulatory Compliance

The announcement was formally communicated to BSE Limited on February 5, 2026, through a regulatory filing. The communication was signed by Sandeep Phadnis, Vice President – Secretarial & Company Secretary of J.B. Chemicals & Pharmaceuticals Limited.

Shareholder Implications

Shareholders who hold equity shares of the company as of the record date will be entitled to receive the interim dividend for FY 2025-2026. The record date serves as the benchmark for determining beneficial ownership and dividend distribution eligibility. Investors planning to participate in the dividend distribution must ensure their shareholding is reflected in the company's records by February 11, 2026.